Human ortholog of Drosophila melted impedes SMAD2 release from TGF-β receptor i to inhibit TGF-β signaling

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 23, 2015, Pages E3000-E3009

  Shathasivam, Premalatha ^a,b   Kollara, Alexandra ^a,b   Ringuette, Maurice J ^b   Virtanen, Carl ^c   Wrana, Jeffrey L ^a,b   Brown, Theodore J ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

ALK5; Melted; SMAD2 3; TGF ; VEPH1

Indexed keywords

DROSOPHILA MELTED PROTEIN; DROSOPHILA PROTEIN; PLECKSTRIN; PROTEIN; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG; VENTRICULAR ZONE EXPRESSED PH DOMAIN CONTAINING 1 PROTEIN; MELTED PROTEIN, DROSOPHILA; SIGNAL PEPTIDE; SMAD2 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ARTICLE; DROSOPHILA; ENZYME INHIBITION; GENE EXPRESSION PROFILING; GENE LOCUS; NONHUMAN; ORTHOLOGY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REPORTER GENE; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; ANIMAL; CELL NUCLEUS; FEMALE; HUMAN; METABOLISM; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

MAMMALIA;

ANIMALS; CELL LINE, TUMOR; CELL NUCLEUS; DROSOPHILA; DROSOPHILA PROTEINS; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; OVARIAN NEOPLASMS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 84931267425     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1504671112     Document Type: Article

References (53)

1. Muto E, et al. (2004) Identification and characterization of Veph, a novel gene encoding a PH domain-containing protein expressed in the developing central nervous system of vertebrates. Biochimie 86(8):523-531.
2. Teleman AA, Chen YW, Cohen SM (2005) Drosophila Melted modulates FOXO and TOR activity. Dev Cell 9(2):271-281.
3. Mikeladze-Dvali T, et al. (2005) The growth regulators warts/lats and melted interact in a bistable loop to specify opposite fates in Drosophila R8 photoreceptors. Cell 122(5):775-787.
4. Jukam D, Desplan C (2011) Binary regulation of Hippo pathway by Merlin/NF2, Kibra, Lgl, and Melted specifies and maintains postmitotic neuronal fate. Dev Cell 21(5):874-887.
5. Jukam D, et al. (2013) Opposite feedbacks in the Hippo pathway for growth control and neural fate. Science 342(6155):1238016.
6. Iwabuchi H, et al. (1995) Genetic analysis of benign, low-grade, and high-grade ovarian tumors. Cancer Res 55(24):6172-6180.
7. Haverty PM, Hon LS, Kaminker JS, Chant J, Zhang Z (2009) High-resolution analysis of copy number alterations and associated expression changes in ovarian tumors. BMC Med Genomics 2:21.
8. Tan DS, et al. (2009) PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin Cancer Res 15(7):2269-2280.
9. Ramakrishna M, et al. (2010) Identification of candidate growth promoting genes in ovarian cancer through integrated copy number and expression analysis. PLoS ONE 5(4):e9983.
10. Schmierer B, Hill CS (2007) TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol 8(12):970-982.
11. Shi Y, Massagué J (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113(6):685-700.
12. Akhurst RJ, Derynck R (2001) TGF-beta signaling in cancer-a double-edged sword. Trends Cell Biol 11(11):S44-S51.
13. Massagué J (2008) TGFbeta in Cancer. Cell 134(2):215-230.
14. Siegel PM, Massagué J (2003) Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 3(11):807-821.
15. Massagué J, Gomis RR (2006) The logic of TGFbeta signaling. FEBS Lett 580(12): 2811-2820.
16. Pardali K, Moustakas A (2007) Actions of TGF-beta as tumor suppressor and prometastatic factor in human cancer. Biochim Biophys Acta 1775(1):21-62.
17. Wang YQ, Qi XW, Wang F, Jiang J, Guo QN (2012) Association between TGFBR1 polymorphisms and cancer risk: A meta-analysis of 35 case-control studies. PLoS ONE 7(8):e42899.
18. Taylor BS, et al. (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18(1):11-22.
19. Imielinski M, et al. (2012) Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150(6):1107-1120.
20. Brennan CW, et al.; TCGA Research Network (2013) The somatic genomic landscape of glioblastoma. Cell 155(2):462-477.
21. Koboldt DC, et al.; Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61-70.
22. Baca SC, et al. (2013) Punctuated evolution of prostate cancer genomes. Cell 153(3): 666-677.
23. Barretina J, et al. (2010) Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 42(8):715-721.
24. Cancer Genome Atlas Research Network (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507(7492):315-322.
25. Kandoth C, et al.; Cancer Genome Atlas Research Network (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497(7447):67-73.
26. Bell D, et al.; Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474(7353):609-615.
27. Barretina J, et al. (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483(7391):603-607.
28. Grasso CS, et al. (2012) The mutational landscape of lethal castration-resistant prostate cancer. Nature 487(7406):239-243.
29. Hammerman PS, et al.; Cancer Genome Atlas Research Network (2012) Comprehensive genomic characterization of squamous cell lung cancers. Nature 489(7417): 519-525.
30. Subramanian A, et al. (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102(43):15545-15550.
31. Mootha VK, et al. (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34(3): 267-273.
32. Dinkel H, et al. (2012) ELM-the database of eukaryotic linear motifs. Nucleic Acids Res 40(Database issue):D242-D251.
33. Iłzecka J, Stelmasiak Z, Dobosz B (2002) Transforming growth factor-Beta 1 (tgf-Beta 1) in patients with amyotrophic lateral sclerosis. Cytokine 20(5):239-243.
34. Krieglstein K, Unsicker K (1996) Distinct modulatory actions of TGF-beta and LIF on neurotrophin-mediated survival of developing sensory neurons. Neurochem Res 21(7):843-850.
35. Walsh JE, Young MR (2011) TGF-beta regulation of focal adhesion proteins and motility of premalignant oral lesions via protein phosphatase 1. Anticancer Res 31(10):3159-3164.
36. Cicchini C, et al. (2008) TGFbeta-induced EMT requires focal adhesion kinase (FAK) signaling. Exp Cell Res 314(1):143-152.
37. Barrios-Rodiles M, et al. (2005) High-throughput mapping of a dynamic signaling network in mammalian cells. Science 307(5715):1621-1625.
38. Zawel L, et al. (1998) Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell 1(4):611-617.
39. Labbé E, Silvestri C, Hoodless PA, Wrana JL, Attisano L (1998) Smad2 and Smad3 positively and negatively regulate TGF beta-dependent transcription through the forkhead DNA-binding protein FAST2. Mol Cell 2(1):109-120.
40. Massagué J, Chen YG (2000) Controlling TGF-beta signaling. Genes Dev 14(6):627-644.
41. Huse M, et al. (2001) The TGF beta receptor activation process: An inhibitor- to substrate-binding switch. Mol Cell 8(3):671-682.
42. Guo X, et al. (2008) Axin and GSK3- control Smad3 protein stability and modulate TGF- signaling. Genes Dev 22(1):106-120.
43. Lu H, Ward MG, Adeola O, Ajuwon KM (2013) Regulation of adipocyte differentiation and gene expression-crosstalk between TGFβ and wnt signaling pathways. Mol Biol Rep 40(9):5237-5245.
44. Grocott T, Johnson S, Bailey AP, Streit A (2011) Neural crest cells organize the eye via TGF-β and canonical Wnt signalling. Nat Commun 2:265.
45. Antony ML, Nair R, Sebastian P, Karunagaran D (2010) Changes in expression, and/or mutations in TGF-beta receptors (TGF-beta RI and TGF-beta RII) and Smad 4 in human ovarian tumors. J Cancer Res Clin Oncol 136(3):351-361.
46. Lynch MA, et al. (1998) Mutational analysis of the transforming growth factor beta receptor type II gene in human ovarian carcinoma. Cancer Res 58(19):4227-4232.
47. Wang D, et al. (2000) Analysis of specific gene mutations in the transforming growth factor-beta signal transduction pathway in human ovarian cancer. Cancer Res 60(16): 4507-4512.
48. Chen T, et al. (2001) Transforming growth factor-beta receptor type I gene is frequently mutated in ovarian carcinomas. Cancer Res 61(12):4679-4682.
49. Sunde JS, et al. (2006) Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancer. Cancer Res 66(17):8404-8412.
50. Chou JL, Chen LY, Lai HC, Chan MW (2010) TGF-β: Friend or foe? The role of TGF- β/SMAD signaling in epigenetic silencing of ovarian cancer and its implication in epigenetic therapy. Expert Opin Ther Targets 14(11):1213-1223.
51. Chou JL, et al. (2010) Promoter hypermethylation of FBXO32, a novel TGF-beta/ SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer. Lab Invest 90(3):414-425.
52. Chan MW, et al. (2008) Aberrant transforming growth factor beta1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer. Neoplasia 10(9):908-919.
53. Sodek KL, Ringuette MJ, Brown TJ (2007) MT1-MMP is the critical determinant of matrix degradation and invasion by ovarian cancer cells. Br J Cancer 97(3):358-367.